While it remains uncertain whether the kidney stone case was directly caused by the rapid weight loss, studies suggest that GLP-1 agoniststhe class of drugs retatrutide belongs tocould contribute to such risks
Some researchers experience mild fatigue , a slight headache, or changes in bowel habits
Sharifi-Rad M, Lankatillake C, Dias DA, Docea AO, Mahomoodally MF, Lobine D, Chazot PL, Kurt B, Boyunegmez Tumer T, Catarina Moreira A, Sharopov F, Martorell M, Martins N, Cho WC, Calina D, Sharifi-Rad J (2020) Impact of natural Compounds on neurodegenerative disorders: from preclinical to pharmacotherapeutics
5.2 Tirzepatide (SURMOUNT Trials) Tirzepatide demonstrated even greater mean weight loss in SURMOUNT trials. Findings included: Weight reductions exceeding 20% in some cohorts Dose-dependent gastrointestinal symptoms Lean mass reduction proportional to total weight loss Again, detailed micronutrient panels were not central trial endpoints
